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Abstract 
We studied the effects of arginine vasopressin (AVP) and somatostatin (SS) on 
glutamate release and characterized the receptors that mediate the effects of these two 
peptides from rat astrocytes. 
Aginine vasopressin (AVP) acts through specific G protein-coupled receptors and not 
only induces [Ca2+]i increase in astrocytes, but also has been shown to regulate astrocytic cell 
volume changes. Here we report a novel finding that AVP induces glutamate release from 
astrocytes isolated from the cerebral cortex and hippocampus. We also investigated the type 
of AVP receptors involved in the A VP-induced increase in glutamate release from astrocytes 
isolated from the hippocampus and cortex of neonatal rats. We showed that the AVP (0.1 -
1000 nM)-induced increase in glutamate release and [Ca2+]i is brought about by two distinct 
subtypes of AVP receptors (Via & Vib). Our results suggested, that Vib receptors are 
predominantly expressed in astrocytes isolated from the hippocampus and Via receptors are 
predominantly expressed in astrocytes isolated from the cortex of neonatal rats. In addition, 
the A VP-induced increase in glutamate did not contribute to an increase in [Ca2+]i, since 
blockade of metabotropic glutamate receptors did not alter the A VP-induced increase in 
[Ca2+]i. Also the administration of a phospholipase A2 (PLA2) inhibitor failed to alter AVP-
induced [Ca2+]i increase, suggesting the lack of involvement of PLA2. 
In the second part of the thesis, we investigated the effects of somatostatin (SS), a G/0-
coupled receptor activating hormone on lowering of cAMP level, [Ca2],, and glutamate 
release from neonatal rat astrocyte cultures. Forskolin (10"7 to 10"5 M) increased glutamate 
release, cAMP levels and [Ca2 ],. in a concentration-dependent manner; forskolin-induced 
increase in [Ca2+]i paralleled the increase in glutamate release, but the increase in cAMP 
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levels did not. SS alone did not have any effect on basal glutamate release, cAMP levels or 
[Ca2+]i, but inhibited the forskolin-induced glutamate release and increase in cAMP level in a 
concentration-dependent manner. Somatostatin also inhibited forskolin induced increase in 
[Ca2+]i. These effects were mimicked by the selective SSTR4 agonist L-803,087, but not by 
the selective agonists for SSTRl, SSTR2, SSTR3 or SSTR5. Although the inhibitory effect 
of SS and L-803,087 (10"9 to 10"6 M) on forskolin-induced increase in cAMP levels and 
glutamate release was concentration-dependent, the inhibition of glutamate release, however, 
was not apparent at >10"6 M of the agonists. This was probably due to the ability of SS and 
L-803,087 to increase [Ca2+]; at >10"6 M. Pretreatment with U-73122, a phospholipase C 
inhibitor, blocked 10"6 M SS-induced increase in [Ca2 ],. Our findings suggest: In astrocytes, 
1) SS inhibits forskolin-induced glutamate release by decreasing cAMP levels and at least 
partly by reducing [Ca2+];. 2) SSTR4 mediates SS-induced decrease in cAMP levels, [Ca2+]i 
and glutamate release. 3) SS at high concentrations (>10"6 M) may increase glutamate release 
by activating phospholipase C pathway. SS or SSTR4 agonists could be used to reduce 
glutamate release from astrocytes. 
1 
Chapter 1. General Introduction 
Thesis Organization 
This thesis is written in an alternative thesis format. It contains a general introduction 
including literature review and a list of references cited, two manuscripts and their 
conclusions along with acknowledgements. 
Literature Review 
Astrocytes: 
Astrocytes (Fig. 1) are a type of glial cells of the central nervous system that were 
thought of as relatively uninteresting support cells of the central nervous system (Virchow, 
R, 1846). Since then studies have shown that astrocytes are complex and play a very 
important role in regulating and maintaining optimal conditions for the nervous system to 
function. Their role as regulators of brain homeostasis is just a part of their repertoire of 
many complex functions. To date, astrocytes are vital not only for the proper development of 
neurons, but also influence many aspects of neuronal functions (Nedergaard et al., 2003). 
Current studies also show that astrocytes may be involved in modulating synaptic 
transmission, CNS plasticity and brain homeostasis (Chen et al., 2000). 
Figure 1. Image of Glial Fibrillary Acidic Protein (GFAP) expressing astrocytes. GFAP is an 
intermediate filament protein of 52kD found in glial cells such as astrocytes and ependymal 
cells and is used as a marker to identify astrocytes. 
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Arginine vasopressin: 
Arginine vasopressin (AVP) is a nonapeptide (Table 1) with two cysteine residues in 
position 1 and 6 linked by a disulfide bridge (Barberis et al., 1998). The amino acids in 
positions 5 (asparagine), 7 (proline) and 9 (glycine) are conserved (Table 1). In all the 
mammals except swine the 8th amino acid is arginine, where as in swine and marsupials there 
is a lysine in the 8th position. AVP is synthesized by the magnocellular neurons of the 
hypothalamus in the para ventricular nucleus (PVN) and supraoptic nucleus (SON) (Swaab et 
al., 1975). AVP is transported (in its prohormone state with 168 amino acids) along the 
supraoptic-hypophyseal tract to the posterior pituitary (Fig. 2), from where it is released into 
the circulation. The preprohormone is processed to remove the signal peptide (residues -23 to 
-1) and is translocated as the prohormone through the rough endoplasmic reticulum to be 
incorporated into large membrane enclosed granules. The prohormone consists of three 
domains: VP (residues 1-9), VP-neurophysisn (residues 13-105) and VP glycopeptide 
(residues 107-145). In the secretory granule the prohormone is further processed to produce 
VP. Furthermore, significant levels of AVP have also been reported in cerebral cortex and 
hippocampus (Toide et al., 1995) pointing at other possible sources of AVP synthesis within 
the brain. AVP synthesis outside the hypothalamic-neurohypophyeal system has been 
reported in the heart (Hupf et al., 1999), pancreas (Méchaly et al., 1999) and pulmonary 
artery (Loesch et al., 1991). The magnocellular neurons of the SON are depolarized by 
hypertonic conditions (more AVP released) and hyperpolarized by hypotonic conditions (less 
AVP released). 
The pressor effects of AVP were first observed in 1895 (Oliver et al., 1895) and was 
attributed to the pituitary extract from the posterior lobe of the pituitary gland. The 
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antidiuretic effects of the pituitary extract were first demonstrated in 1913 (von den Velden, 
1913). AVP was isolated and synthesized in the 1950s and both the pressor and antidiuretic 
effects were attributed to the same hormone (Turner et al., 1951; Du Vigneaud et al., 1954). 
AVP has been shown not only to regulate body fluid volume, osmolality and blood 
pressure, but also act as a neurotransmitter (Craig et al., 1997), regulate cell volume 
(Sarfaraz, 1999), plasma volume (Hayashi et al., 2006), potassium ion balance (Martha 
O'Donnell, 2005), chloride ion efflux (Good, 1990) and cognitive and behavioral functions 
and memory processes (Bielsky et al., 2003). In addition, AVP has also been reported to 
inhibit glutamate release from neurons of nucleus tractus solitarius (Bailey et al., 2006). 
H 
ormone Position of amino acid residues 
Ancestral Molecule Cvs1-Tyr2-X3-X4-Asn5-Cvs6-Pro7-X8-Glv9-flS[H7) 
Arginine 
vasopressin 
CyS1-Tyr2-Phe3-Gln4-Asn5-Cys6-Pro7-Arg8-Gly9-(NH2) 
Lysine 
Vasopressin 
CyS1-Tyr2-Phe3-Gln4-Asn5-Cys6-Pro7-Lys8-Gly9-(NH2) 
Table 1. Amino acid sequence of vasopressin (AVP) (modified from Hadley, 1992). 
5 
Signal 
Peptide VP Neurophysin | VP-Glycopepticte 'COOH 
Signal peptide 
2Arg 
•'A O; 
•Carbohydrate 
Lys 
OHC-COOH 
> f 
AVP VP Neurophysin VP Glycopeptide 
Figure 2. Processing of the 168-amino acid prepro-AVP to AVP, VP-Neurophysin and VP-
Glycopeptide (modified from Pickering, 1995). 
AVP release: Several factors influence AVP release and can be broadly classified as 
Osmoregulation: Osmoreceptors in the hypothalamus regulate AVP release. Increases in 
plasma osmolality cause shrinkage of the osmoreceptor cells, which in turn alters the electric 
activity of the neurons and stimulates AVP release. The released AVP causes antidiuresis and 
makes urine more concentrated. 
Volume regulation: Stretch receptors (baroreceptors) in the left atrium can sense the 
decrease in plasma volume and stimulate the release of AVP by reducing the tonic inhibitory 
pulses from the left atrium to the hypothalamus. The neural impulses reach the SON and 
PVN through the vagus nerve and stimulate AVP release into the circulation. 
Baroreceptor regulation: Activation of carotid and aortic stretch receptors (baroreceptors) in 
response to hypotension also causes release of AVP. Hypotension-induced stimulus can raise 
the plasma concentration of AVP to 1000 times the normal levels and cause vasoconstriction. 
Apart from the above mentioned stimuli for AVP secretion, cholinergic and beta-
adrenergic stimulation of hypothalamus can increase AVP secretion while alpha 2-adrenergic 
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stimulation can inhibit AVP secretion. Emotional stress and pain may also increase AVP 
secretion (Alexander et al., 1988). 
G-proteins: 
The actions of AVP are mediated (Fig. 4) through specific receptors of the class G-
protein coupled receptors (GPCRs). Guanine nucleotide binding proteins (G-proteins) are a 
family of proteins involved in second messenger signaling cascades and are found 
predominantly at the inner aspect of the plasma membrane. They form the link between the 
receptor and down stream effectors. G-proteins fall into two distinct classes - heterotrimeric 
G-proteins and monomelic G-proteins. The exchange of GDP for GTP activates the G-
protein. 
Heterotrimeric/large G-proteins are comprised of three different molecules (subunits) 
a, P and y. The a-subunit has the binding site for GDP and GTP and hence acts like a 
regulator. GTP bound a-subunit is the active form, which dissociates from the Py subunits 
and the GDP bound a-subunit is tightly associated with the Py subunits. Based on sequence 
and functional similarities of the a-subunit, heterotrimeric G proteins can be classified into 4 
families - Gs, G/0, Gq and G12/13 (Simon et al., 1991). The Gs a subunit can stimulate 
adenylyl cyclase (Taussig et al., 1995). The G/0 family a subunits can inhibit adenylyl 
cyclase, while the a-subunit of the transducin, which also belongs to G, family can stimulate 
cGMP-phosphodiesterase (Taussig et al., 1995). The a subunit of Gq family can stimulate 
phospholipase CP and Gi2 has been shown to activate several GTPases Ras, Rac, CDC42, 
and Rho (Radhika et al., 2001). 
The monomeric G-proteins, usually referred to GTPases, are comprised of a single unit 
and are not directly coupled to the receptors. Their functions are similar to a subunit of 
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heterotrimeric G proteins. Normally they are bound to GDP and inactive and their activation 
is usually several steps downstream to the receptor activation. To date, about 150 eukaryotic 
small G proteins have been identified and divided into five families - Ras, Rho, Rab, 
Sarl/Arf and Ran (Takai et al., 2001). Ras and Rho families are involved in gene expression, 
Rho proteins regulate cytoskeleton reorganization, Rab and Sarl/Arf proteins influence 
vesicular transport. Ran has been shown to regulate nuclear transport and the cell cycle 
(Marcin et al., 2001). 
AVP receptors structure, distribution and function: 
Three types of receptors for AVP have been identified and are classified as Via (Vi), 
V2 and Vib (V3) (Thibonnier et al., 1998). These receptors are GPCRs comprised of typical 
seven transmembrane a helices joined by intracellular and extracellular loops. 
Gene for the Via (also called as Vi) maps to chromosome 12 (Thibonnier et al., 1996) 
and the Via receptor activates G-proteins of the Gq/n family. Via receptors are widespread 
and are found in brain, testis, liver, cervical ganglion, liver, blood vessels and renal medulla 
(Phillips et al., 1990). 
Gene for Vib (also called as V3) receptor maps to chromosome l(Sugimoto et al., 
1994; Rousseau et al., 1995). Vib receptor acts through Gq/n family of G-proteins and has 
been reported to be present in anterior pituitary (Thibonnier et al., 1998) and pancreas (Lee et 
al., 1995). Vib receptor mRNA has also been reported in other peripheral tissues (kidney, 
thymus, heart, lung, uterus, breast) as well as in the anterior pituitary (Loiait et al., 1995). 
Gene for V2 receptor maps to chromosome 10. V2 receptors, which act through G-
proteins of the Gs class, have been reported to be present in the renal collecting tubules 
(Birnbaumer, 2000). The V2 receptor differs from the Vi (Via & Vib) class of receptors in the 
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number of sites available for N-linked glycosylation; the Vi (Via & Vn-,) receptors have sites 
at both the amino-terminus and at the extracellular loop, whereas the V? receptor has a single 
site (Fig.3a & 3b) at the extracellular amino-terminus (Innamorati et al., 1996). 
>0® 
Figure 3a. Human V? receptor transmembrane topology showing the single site of N-linked 
glycosylation in the amino terminus (modified from Sadhegi et al. 1997) 
Figure 3b. Human Via receptor transmembrane topology showing sites of N-linked 
glycosylation in the amino terminus (modified from Barberis et al., 1998). 
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jÂL, 
AVP 
Figure 4. Gs and Gq signaling mechanism for AVP receptors. 
ATP: Adenosine triphosphate, AC: Adenylyl cyclase, AVP: Arginine vasopressin, Ca++: 
Calcium, cAMP: Cyclic adenosine monophosphate, DAG: Diacyl glycerol, ER: Endoplasmic 
reticulum, Gq: Gq coupled GPCR, Gs: Gs coupled GPCR, GTP: Guanosine triphosphate, 
GDP: Guanosine diphosphate, PKA: cAMP dependent protein kinase, PIP?: Phosphatidyl 
bisphosphate, PLC: Phospholipase C. 
G-protein mediated AVP action: 
Binding of AVP with Via/Vib receptors activates phospholipase C (PLC) (Barberis et 
al., 1998). Activation of PLC leads to hydrolysis of phosphatidylinositol-4, 5-bisphosphate 
(PIP2), which generates the second messengers inositol 1,4,5-tris-phosphate (IP3) and 
diacylglycerol (DAG). IP3 acts on its receptors on the endoplasmic reticulum leading to Ca2+ 
release from this organelle, while DAG activates protein kinase C (PKC) (Martin et al., 
2004). The Ca2+ release activates Ca2+ release-activated Ca2+ current channels (ICRAC) on 
the plasma membrane (Mathes et al., 1998) leading to a sustained Ca2+ influx (Putney, 1990). 
Stimulation of V%a receptors located in the vascular smooth muscle causes vasoconstriction, 
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whereas Vib has been shown to regulate ACTH release by potentiating the effects of CRH 
(Aguilera et al., 2000), mediate insulin (Lee et al., 1995) and glucagon (Yibchok-anun et al., 
1998) release from pancreatic islets. 
Binding of AVP to V? receptors activates the adenylyl cyclase pathway, leading to 
increase in intracellular cAMP levels (Birnbaumer, 2000). The increased intracellular cAMP 
in the kidney (Orloff et al., 1967; Dousa et al., 1972) in turn triggers fusion of aquaporin-2-
bearing vesicles with the apical plasma membrane of the collecting tubule, leading to 
increased water reabsorption (Harris et al., 1994). 
AVP receptor antagonists: 
Several selective antagonists against Via, Vib and V? have been synthesized ever since 
the structure of AVP had been deciphered (du Vigneaud et al., 1954). The antagonists (fig. 5) 
are available as both peptide and nonpeptide derivatives. The peptide antagonists are both 
cyclic and linear peptides. [l-(P-mercapto-P,P-cyclopentamethyleneproprionic acid),2-0-
methyltyrosine]AVP also known as d(CH2)5[Tyr(Me)2]AVP (pA2 = 8.62) (Manning et al., 
1989) and desGly9d(CH2)5[Tyr(Et)2]AVP (WK-3-6) (pA2 = 8.17) (Jard et al., 1992) are 
potent Via receptor antagonists. 
These antagonists are widely used in pharmacological studies but highly specific 
peptide antagonists for Vib receptors are still not available currently. [1-
deaminopenicillamine, 2-0-methyltyrosine]AVP (dP[Tyr(Me)2]AVP) is the most potent Vib 
antagonist (Manning et al., 1989) with a K; of 9.7 nM. It also shows low affinity for V2 
receptors and also blocks Via receptors (pA2 = 7.96) (Schlosser et al., 1994). 
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4-OHphenacetyl-D-Tyr(Me)-Phe-Gln-Asn-Arg-Pro-Arg-NH2 (CL4-84) is a linear 
peptide antagonist that has a high affinity for Vib receptor (K; = 2.2 + 0.1 nM) (Thibonnier et 
al., 1997). It also has potent anti Via (pA2 = 8.74) activity (Jard et al., 1986). 
d(CH2)5[D-Phe2, Ile4]-AVP (AO-2-44) is another potent peptide antagonist for 
V2/Via/Vib receptors with pA2 values of 7.83 and 8.16 for anti-Via and anti-V2 respectively 
(Jard et al., 1986). 
Several non-peptide antagonists (Fig. 6) have also been designed and are available 
for studies. ((2S, 4R)-l-[5-chloro-l-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxyphenyl)-
2-oxo-2,3-dihydro-lH-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrollidine carboxamide, 
isomer(-)) (SSR-149415) is a highly specific nonpeptide Vib receptor antagonist (K, = 1.3 to 
5 nM) (Serradeil Le-Gal et al., 2002). (2S) 1-[(2R 3S)-(5-chloro-3-(2-chlorophenyl)-l-(3,4-
dimethoxybenzene-sulfonyl)-3-hydroxy-2,3-dihydro-lH-indole-2-carbonyl]-pyrrolidine-2-
carboxamide (SR-49059) (K; = 1.6 + 0.2 nM) is highly specific nonpeptide Via receptor 
antagonist (Serradeil Le-Gal et al., 1993). (l-[4-(N-tert-Butylcarbamoyl)-2-methoxybenzene 
sulfonyl]-5-ethoxy-3-spiro-[4-(2-morpholinoethoxy)cyclohexane]indoline-2-one, phosphate 
monohydrate; cis-isomer) (SR-121463B) is a selective nonpeptide antagonist for V2 receptors 
(Viviane et al., 2003; Serradeil Le-Gal et al., 1996). 
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1 2 3 4 5 6 7 8 9 
CH2-CO-Tyr(Me)-Phe-Gln-Asn-Cys-Pro-Arg-Gly-NH2 
(A) 
CH3 
CH3 
1 2 3 4 5 6 7 8 9 
CH2-CO-Tyr(Me)-Phe-Gln-Asn-Cys-Pro-Arg-Gly-NH2 
I 
(B) 
Figure 5. Structure of AVP receptor antagonists A) d(CH2)5[Tyr(Me)2]AVP; B) 
dP[Tyr(Me)2]AVP (modified from Manning and Sawyer, 1989). 
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SSR-149415 SR-121463 
HO, CI. 
CON 
H CONH 
OCH 
SR-49059 
Figure 6. Structure of nonpeptide AVP receptor antagonists (Modified from Serradeil-Le Gal 
et al. 2002, 1996, 1993). 
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Glutamate: 
Glutamate was first proposed as a neurotransmitter by Hayashi (1954) and was shown 
to depolarize and excite central neurons (Curtis et al., 1959). Over the years glutamate has 
been shown to be a major excitatory neurotransmitter in brain (Lebon et al., 2001) and major 
pools of glutamate are concentrated in glutamatergic neurons (Shepherd, 1994) and 
astrocytes (Nicholls, 1989). The metabolism of glutamatergic neurons and astrocytes are 
coupled through a glutamate-glutamine cycle (Fig. 7), where in some of the glutamate 
released from nerve terminals, is transported into the surrounding glial cells. The glutamate is 
converted to glutamine which is then transported out of the glia and absorbed into neurons, 
where it is converted back to glutamate (Rothman et al., 2003). Apart from the glutamate 
taken up from the synaptic clefts, astrocytes utilize glucose to synthesize glutamate (Aureli et 
al., 1997). Interruption of this exchange leads to impairment of glutamatergic 
neurotransmission (Keyser et al., 1994). Astrocytes express the highest density of glutamate 
transporters (Huang et al., 2004) and hence take up a high quantity of synaptic glutamate 
(Magistretti et al., 1999) and regulate extracellular glutamate levels, thus protecting the 
neurons from glutamate toxicity. Furthermore, glutamate has also been shown to induce 
astrocytic swelling (Hansson et al., 1994). 
Glutamate receptors: 
Glutamate mediates its effects through specific receptors and these receptors fall 
under two major subgroups - ionotropic glutamate receptors (iGluRs) and metabotropic 
glutamate receptors (mGluRs). iGluRs directly gate ion channels, while mGluRs are coupled 
to other intracellular messenger systems and may also activate ion channels. The ionotropic 
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Astrocyte 
Glutamine giy — 
<100 mM) 
Synapse 
V WV 
glutamate receptors are further classified into two groups based on whether they bind to the 
glutamate analogue N-Methyl-D-Aspartate (NMDA). The non-NMDA receptors are further 
divided into groups based on the selectivity by the agonists alpha-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid (AMPA), Kainate and quisqualate. NMDA receptors, upon 
glutamate binding, open up nonselective cation channels, which are more permeable to Ca2+. 
Non-NMDA receptors upon glutamate binding, open nonselective cation channels, which are 
more permeable to Na+ and K+ (Mayer et al., 1987). Metabotropic glutamate receptors are 
further classified (Table 2) into three groups (Group I, II & III) (Knopfel et al., 1995). Group 
I metabotropic glutamate receptors are coupled Gq class of GPCRs and its stimulation leads 
to increase in IP3 and release of Ca2+ from endoplasmic reticulum. Group II and group III 
receptors are coupled to G/0 class of GPCRs which, when activated, decrease cAMP by 
inhibiting adenylyl cyclase (Pin et al., 1995). The Group II and Group III receptors are 
classified based on their agonist selectivity. 
Blood 
Glutamine # m 
Gb 
C3Q-80 (iM) 
Glutamate < 1uM 
tfïU - larrM 
Figure 7. Astrocytes - Glutamate homeostasis (Modified from nature reviews). 
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Group 
mGluR Signal Pathway 
I mGluRl 
mGluRS 
Gq 
II mGluR2 
mGluRS 
Gi/o 
III mGluR4 
mGluR6 
mGluR7 
mGluRS 
Gi/o 
Table 2. Metabotropic glutamate receptors family and their functions. 
Receptor subtypes Species Orgaji Ussue/CelJ type 
GJuR 21/3, Ka 2, NMDAR I, Rat/mojikey Heart Atrium/septum conducting fibers, 
mGluR 5, mGJuR 2/3, ganglia cells, nerve fibers, 
mGluR 1 mvocardiocytes, intercaJated 
discs, blood vesseJs 
GluR 2/3, Ka 2, NMDAR I, Rat/mojikey Ovary Corpus hiteum, primordial follicles, 
mGluR 2/3 theca, granulosa cells, oocyte, 
blood vessels, nerve fibers 
GJuR 2/3, Ka 2, NMDAR I, Rat/mojikey Uterus Exocervix, myometrium, 
GluR 2/3 endometrial glands, epithelium 
of fallopian tubes, nerve fibers 
GJuR 2/3, Ka 2, NMDAR 1, Rat Kidney Glomeruli, mesangium, 
mGluR 2/3 podocytes, juxtaglomerular 
apparatus, tubules 
GJuR 2/3, Ka 2, NMDAR 1, Rat Testis Germinal epithelium, 
mGluR 2/3 interstitial cells 
GJuR 2/3, Ka 2, NMDAR I, Rat Gastrointestinal Enteroendocrine cells, parietal cells 
mGluR 2/3 of the stomacJi, pancreatic islets, 
nerve fibers, ganglia cells, liver 
GJuR 2/3, Ka 2, NMDAR I, Rat Others Lungs, spleen, bone marrow 
mGluR 2/3 (megakaryocytes), mast cells, 
inflammatory cells 
Table 3. Distribution of glutamate receptors in peripheral tissue (Modified from Gill et al., 
2001). 
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Somatostatin synthesis and release: 
Since its unexpected discovery in 1972 (Brazeu et al., 1973) somatostatin (SS) has not 
only been reported to inhibit the release of growth hormone (Krulich et al., 1969), but also 
inhibit the secretion of endocrine pancreas (Skamene et al., 1984; Yao et al., 2001). 
SS is synthesized as a preprohormone from the long arm of chromosome 3 (Patel et al., 
1999) and the preproSS is further processed into a 14 amino-acid and a 28 amino-acid (SST-
14 and SST-28) SS (Ganong, 2001). There is a considerable variation in the amount of SST-
14 and SST-28 found in various tissues with SST-14 being exclusive form in enteric neurons 
and peripheral nerves in the retina and SST-28 being the dominant form in neural tissue, 
endocrine pancreas and the stomach (Patel et al., 1999). 
The processed SS is released through an exocytotic pathway (Patel et al., 1999) from 
the neurons and 5 cells of the pancreatic islets. SS release can be stimulated by growth 
hormone-releasing hormone, corticotropin-releasing hormone and neurotensin through G-
protein coupled receptors (Patel et al., 1999). Gamma aminobutyrate (GABA) can inhibit SS 
release through both the ionotropic GABAa (hyperpolarization and inactivation of L-type 
VDCC) and G/0-coupled GABAb receptors. In the pancreas, SS release can be stimulated by 
glucagon, glucose, lipids and amino acids (Patel, 1999). 
Somatostatin receptors: 
Five receptor subtypes have been reported through which SS mediates its effects 
(Bruno et al., 1992, Yamada et al., 1992). All these receptors are GPCRs, sensitive to 
pertussis toxin (PTX) and are G/0 coupled (Patel, 1999) with a good degree of conservation 
among species (Reisine et al., 1995). The SSTR2 is subdivided into SSTR2A and SSTR2B 
due to the difference in the length of the cytoplasmic tail with the SSTR2A having a longer 
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cytoplasmic tail than SSTR2B. SSTR1-SSTR4 show a similar binding affinity towards both 
SST-14 and SST-28, but SSTR5 shows higher binding affinity to SST-28 (Patel et al., 1994; 
1995; 1996). All 5 subtypes of SSTRs are expressed in pancreatic islets and stomach (Patel 
1999; Weckbecker et al., 2003). SSTR1 and SSTR2 have been reported in the kidney and all 
subtypes have been reported in liver, lymphocytes, T cells, lungs and lymphoid tissue (Patel 
1999; Weckbecker et al., 2003). SSTR1, 2, 3 and 4 have been reported in brain (Patel 1999; 
Bruns et al., 2003) with pituitary gland expressing SSTR1-3 and SSTRS (Patel 1999; 
Weckbecker et al., 2003). Presence of multiple receptor subtypes in a given tissue and in 
different tissues suggests different physiological responses mediated by the different receptor 
subtypes. 
Changes in S S binding sites have been associated with a number of pathological 
conditions. At the pituitary level, the number of S S binding sites has been negatively 
correlated in case of acromegaly and gliomas are rich in SS binding sites (Epelbaum et al., 
1989). In neurodegenerative diseases such as Alzheimer's and Parkinson's, cortical SS 
concentrations are decreased and there is also a decrease in SS-binding sites in Alzheimer's 
disease (Kumar, 2005). 
Actions of somatostatin: 
The major actions of SS are antiproliferative (Patel et al., 1999), inhibition of hormone 
secretion - growth hormone from the pituitary and also inhibition of secretions from various 
organs (Bertherat et al., 2003). In the central and peripheral nervous system, SS acts as a 
neurotransmitter, inhibiting the release of other neurotransmitters and hormones such as 
glutamate (Dal Monte et al., 2003; Grilli et al., 2004)), dopamine, norepinephrine, 
thyrotropin releasing hormone and thyroid stimulating hormone (Gray et al., 1989; Patel, 
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1999). SS can also inhibit secretions of the gastrointestinal tract and pancreas, such as 
gastrin, vasoactive intestinal peptide, insulin, glucagon, gastric acid, pepsin and bile salt 
(Ganong, 2001; Patel, 1999). 
SSTRs upon activation inhibit adenylyl cyclase activity (Patel et al., 1994) through a 
subunit of G/0, thus lowering the cAMP levels. However, at high agonist concentrations, 
human SSTRS expressed in COS-7 (Akbar et al. 1994) or CHO-K1 cells (Carruthers et al. 
1999) can also cause an activation of adenylate cyclase. SSTRs can also activate 
phospholipase A2 (PLA2) (Duerson et al., 1996) leading to production of arachidonic acid 
which has been implicated in inhibiting glutamate uptake by astrocytes (Marin et al., 1993). 
SS binding can directly activate diverse K+ channels, such as large conductance Ca2+-
activated K+ channels (White et al., 1991), inward- (Sims et al., 1991) and delayed rectifying 
K+ channels (Wang et al., 1989; Raynor et al., 1991) and ATP-sensitive K+ channels (de 
Weille et al., 1989). A few groups have even reported inhibition of inwardly rectifying K+ 
channels (Karschin et al., 1994). In addition SS has also been shown to activate C (PLC)-
PKC (Rosskopf et al., 2003), increase [Ca2+]i (Cheng et al., 2002), modulate mitogen-
activated protein (MAP) kinase signaling (Patel et al., 1999) and activate serine/threonine 
protein phosphatases such as calcineurin (Gromada et al., 2001). SS-induced inhibition of 
voltage dependent Ca2+ channels has been demonstrated in B lymphoblasts (Rosskopf et al., 
2003). SS has been shown to down regulate the expression and release of endozepines from 
cultured astrocytes (Masmoudi et al., 2005). 
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SSTR peptide and non peptide agonists: 
Peptide and nonpeptide agonists based on the structure of the different SSTRs and 
specific to each subtype SSTR are available. Their properties are summarized as shown in 
table 4. In the peptide agonists, Phe7, Trp8, Lys9 and Thr9 are important for the function and 
structural specificity with DTrp and Lys being the essential residues for the P turn (Patel, 
1999). Most SSTR peptide agonists have higher affinities for more than one SSTR subtype 
and hence they are less selective than the nonpeptide agonists. 
L-363,377 a cyclic hexapeptide SSTR2 antagonist forms the basis for modeling and 
synthesis of other SSTR subtype nonpeptide agonists (Schaeffer et al., 1998). Out of 
approximately 200,000 random compounds created from L-363,377 modeling L-264,930 is 
the most potent SSTR2 agonist. L-264,930 through further combinatorial chemistry has been 
used to develop L-797,591, L-779,976, L-796,778, L-803,087 and L-817,818 which are 
highly potent and specific SSTR1, SSTR2, SSTR3, SSTR4 and SSTRS nonpeptide agonists, 
respectively (Schaeffer et al., 1998). 
SSTR peptide and nonpeptide antagonists: 
Peptide antagonists for SSTRs are based on the basic octapeptide template 
(Weckbecker et al., 2003) and have a Lys4-DTrp5, which forms the center of a P turn critical 
for the receptor recognition (Hocart et al., 1999). PRL-2868 and PRL-2903 are SSTR1 and 
SSTR2 octapeptide antagonists, respectively and have the P turn conformation with cyclic 
hexapeptide core having a disulfide bond between Cys2 and Cys7 (Hocart et al., 1999). 
SST3-ODN-8 is cyclic octapeptide antagonist for SSTR3, which has an N-methyl-amino-2-
napthoyl aminoglycine instead of tryptophan in P turn and has a disulfide bond between Cys1 
and Cys8 (Weckbecker et al., 2003). TT-232 a heptapeptide is an antagonist for SSTR4 and 
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has a cyclic pentapeptide core formed with a disulfide bond between Cys2 and Cys6 
(Weckbecker et al., 2003). BIM-23056 is a linear octapeptide antagonist for SSTR5. 
SRA-880 is a nonpeptide antagonist derived from octahydrobenzoquinoline (Hoyer et 
al., 2004) and is specific to SSTR1. BN-81674 is a nonpeptide antagonist for SSTR3 and is 
derived from tetrahydro-P-carboline (Poitout et al., 2001). Nonpeptide antagonists for 
SSTR2, SSTR4 and SSTR5 are still not available. Overall the nonpeptide antagonists are 
more selective and specific than the peptide antagonists (Table 4). 
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Compound hSSTRl 
IC50 (nM) 
hSSTR2 hSSTR3 hSSTR4 hSSTR5 
Peptide agonists 
SMS 201-995 290 0.4-2.1 4.4-34.5 >1000 5.6-3.2 
BIM23014 500 0.5-1.8 43-107 66 0.6-1.4 
RC-160 >1000 5.4 31 45 0.7 
DC32-87 7820 0.65 244 970 6.8 
DC32-92 98 18 5.6 127 1.2 
Nonpeptide agonists 
L-797,591 1.4 1875 2240 170 3600 
L-779,976 2760 0.05 729 310 4260 
L-796,778 1255 >10,000 24 8650 1200 
L-803,087 199 4720 1280 0.7 3880 
L-817,818 3.3 52 64 82 0.4 
Peptide antagonists 
PRL-2868 37+9.5 176+88 382+181 >1000 971+411 
PRL-2903 >1000 26+3.1 231+102 >1000 535+116 
PRL-3195 1000 17.5+5.5 66+5.8 1000 5.98+0.91 
SST3-ODN-8 >10,000 >10,000 6.7 >10,000 >10,000 
TT-232 >10,000 >10,000 >10,000 900 >10,000 
BIM23056 337 132 177 234 12.1 
Nonpeptide antagonists 
SRA-880 9.8 36300 8710 15100 1445 
BN-81674 >10000 >10000 0.92 >10000 >10000 
Table 4. Agonists and antagonists for SSTRs (modified from Hocart et al., 1999; Patel 1999 
and Weckbecker et al., 2003). 
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Chapter 2. Arginine vasopressin increases glutamate release and intracellular Ca2+ 
concentration in hippocampal and cortical astrocytes through two distinct receptors 
Nasser Syed, Catherine Martens, Walter H. Hsu. 
(To be submitted to the Journal of Neurochemistry) 
Abstract 
Aginine vasopressin (AVP), released from the CNS, plays an important role in 
regulating several aspects of CNS functions including stress and cognition. A VP acts through 
specific G protein-coupled receptors and not only induces [Ca2+]i increase in astrocytes, but 
also has been shown to regulate astrocytic cell volume changes. Here we report a novel 
finding that A VP induces glutamate release from astrocytes isolated from the cerebral cortex 
and hippocampus. We also investigated the type of A VP receptors involved in the AVP-
induced increase in glutamate release from astrocytes isolated from the hippocampus and 
cortex of neonatal rats. We showed that the A VP (0.1 - 1000 nM)-induced increase in 
glutamate release and [Ca2+]i is brought about by two distinct subtypes of A VP receptors 
(Via & Vib). Our results suggested, that Vib receptors are predominantly expressed in 
astrocytes isolated from the hippocampus and Via receptors are predominantly expressed in 
astrocytes isolated from the cerebral cortex of neonatal rats. In addition, the A VP-induced 
increase in glutamate did not contribute to an increase in [Ca2+]i, since blockade of 
metabotropic glutamate receptors did not alter the A VP-induced increase in [Ca2+]i. In 
addition, the administration of a phospholipase A2 (PLA2) inhibitor failed to alter A VP-
induced [Ca2+]i increase suggesting the lack of involvement of PLA2. 
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Astrocytes express a repertoire of receptors and play a major role in brain homeostasis 
(Chen et al., 2000) by providing a link between vasculature and neurons. Astrocytes not only 
communicate with each other through Ca2+ waves, but also communicate with neurons 
through regulation of extracellular glutamate concentration (Schousboe et al., 2004). 
Although the exact mechanism of glutamate release from astrocytes is not yet clear, 
sufficient data exist to suggest a Ca2+-dependent exocytotic process (Parpura et al., 2004). 
Several proteins and molecules required for exocytotic process have been shown to be 
present in astrocytes (Bezzi et al., 2004; Enrico et al, 2004; Montana et al., 2004). A highly 
effective regulatory mechanism must be in place to control the extracellular glutamate as 
increased extracellular concentrations can cause neurotoxicity and cell death (Schousboe et 
al., 2004). Thus, in glutamatergic neurotransmission astrocytic glutamate transporters are 
important in the termination of the neurotransmission process (Schousboe, 2003). The 
multifaceted role of astrocytes points in the direction that they are also involved in brain 
information processing, modulating synaptic transmission and CNS plasticity (De Luca et al., 
1997; Klimkiewicz, 2001). 
A VP, a neuropeptide synthesized in paraventricular, supraoptic and suprachiasmatic 
nuclei of the hypothalamus and the media amygdala, is not only involved in regulating the 
water balance (Dibas et al., 1998), but has also been shown to stimulate the Na+-K+-CV 
cotransporter in the blood brain barrier (O'Donnell et al., 2005), and regulate cognitive 
functions, memory, aggression, stress and behavior (Bielsky et al., 2003). In addition, A VP-
positive neurons have been reported in hippocampus (Tiberiis et al., 1983; Orlowska-Majdak 
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et al., 2003) and cerebral cortex (Delville et al., 1994) suggesting A VP synthesis outside the 
hypothalamus. To date, three types of G-protein coupled receptors (GPCRs) for A VP (Via, 
Vib and V2) have been identified (Thibonnier et al., 1998). The V2 receptors are 
extensively/exclusively found in renal tubules, whereas the Via receptors are found in 
vascular smooth muscles, myometrium, urinary bladder, liver, platelets, spleen, testis, 
epithelial cells of the renal cortical collecting duct and many CNS structures including 
astrocytes in brain (Barberis et al., 1998; Jackson 2001). The Vib receptors have been 
reported in adenohypophysis and the Vib mRNA has been detected in kidneys, thymus, heart, 
lung, spleen, some regions of brain (Loiait et al., 1995) and in pancreas (Saito et al., 1995). 
However, little is known about the distribution of receptor subtypes in different regions of 
brain. The V2 receptor activation stimulates Gs protein, adenylyl cyclase (Birnbaumer, 2000) 
and cAMP-dependent protein kinase (PKA). Activation of Via and Vib receptors stimulates 
Gq proteins, phospholipase C (PLC), phospholipase D (PLD) and phospholipase A2 (PLA2) 
(Briley et al., 1994). PLC activation results in production of IP3 and diacylglycerol leading to 
an increase in [Ca2+];, activation of protein Kinase C (PKC) and further downstream protein 
phosphorylation. 
Our present study was to investigate whether A VP, which elicits a Ca2+ response in 
astrocytes, would also increase glutamate release and to characterize the specific receptors 
involved in the A VP-induced increase in glutamate release and [Ca2+];. Via and Vib receptors 
have been reported in astrocytes (Barberis et al., 1998) but whether these receptors are 
differentially expressed or homogenously distributed in astrocytes from different regions of 
the brain is still not yet clearly established. This identification is especially important since 
many treatments directed at A VP receptors have been proposed for various conditions 
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ranging from trauma-induced brain edema to disorders of memory, stress and cognitive 
functions. Taken together our results suggests that in neonatal rats, A VP-induced increase in 
glutamate release and [Ca2+]i is mediated via Vib receptors in astrocytes isolated from the 
hippocampus and by Via receptors in astrocytes isolated from the cerebral cortex. 
Furthermore, the A VP-induced increase in [Ca2+]i was neither blocked by metabotropic 
glutamate receptor antagonist or the phospholipase A2 inhibitor suggesting, glutamate release 
is secondary to increase in [Ca2+]; and lack of PLA2 involvement in this pathway 
respectively. 
Materials and Methods 
Chemicals: dP[Tyr(Me2)]AVP, L-glutamic dehydrogenase (GDH), ^-nicotinamide adenine 
dinucleotide (PNAD), Protease inhibitor cocktail, CelLytic-M lysis buffer (Sigma Chemicals, 
St. Louis, MO), fura-2 acetoxymethyl ester (fura-2AM) (TEF Labs, Austin, TX), , 
desGly9d(CH2)5[Tyr(Et2)]AVP (WK-3-6) (donated by Dr. M Manning, University of 
Toledo, Toledo, OH), 7-(hydroxyimino)cyclopropan-[b]chromen-la-carboxylic acid 
ethylester (CPCCOEt), N-(p-amylcinnamoyl)anthranilic acid (ACA) (Biomol, Plymouth 
Meeting, PA), (l-[4-(N-tert-Butylcarbamoyl)-2-methoxybenzene sulfonyl]-5-ethoxy-3-spiro-
[4-(2-morpholinoethoxy)cyclohexane]indoline-2-one, phosphate monohydrate; cic-isomer) 
(SR-121463B) (donated by Dr. C. Serradeil-Le Gal, Sanofi-Synthelabo Rech, Toulouse 
Cedex, France). Antisera vs. Via and Vib receptors (Santa Cruz Biotech, Santa Cruz, CA). 
Cell culture 
Cell cultures were established according to a previously described procedure (Jeftinija 
et al. 1996). Briefly, primary culture of astrocytes was established from cells isolated from 
the hippocampus and cerebral cortex of 1 - 4 day old Sprague-Dewley rats. Following 
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trypsinization, the cells were plated in culture flasks containing a-MEM supplemented with 
10% FBS and maintained at 37°C until they reached 90% confluency. The confluent cultures 
were further processed to obtain enriched astrocyte type I cultures by preshaking at 260 RPM 
in an orbital shaker for 2 h to remove microglia and dividing astrocytes. After preshaking the 
media was changed and the cultures were incubated for 1 h to equilibrate before they were 
shaken overnight at 260 RPM. Following the shaking the supernatant was discarded and the 
adhering astrocytes were trypsinized and resuspended in new flasks with FBS supplemented 
a-MEM. Cells from passage 2 to 6 were used for all the experiments. For glutamate 
measurement, cells were plated on 2-mm coverslips and used after they reached confluency 
by placing the cover slip in an open peri fusion chamber. For calcium imaging experiments, 
the astrocytes were plated in a central 15-mm diameter well in a 35-mm dish and used after 
24 h of culture. 
Immunocytochemistry 
The cells were confirmed as astrocytes by their morphology and positive staining for 
glial flbrilary acidic protein (GFAP) marker using immunocytochemistry (Hsu et al., 1981). 
Immunocytochemistry was performed by using antibodies against GFAP. 
Glutamate measurement 
Glutamate levels were detected using an enzymatic assay as previously described 
(Nicholls et al., 1986; Nicholls et al., 1987; Ayoub et al., 1998; Innocent! et al., 2000). L-
glutamic dehydrogenase (GDH) converts ^-nicotinamide adenine dinucleotide (PNAD) to 
NADH in the presence of glutamate and NADH fluoresces when excited with UV light. By 
providing GDH and PNAD in the medium in which astrocytes are bathed, the glutamate 
released into the medium can be detected as an increase in NADH fluorescence signal. 
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The enzymatic assay solution in which the cells were bathed was composed of NaCl, 
137 mM; KC1, 5 mM; MgCh, 2 mM; CaCh, 2 mM; HEPES, 10 mM; glucose, 10 mM. The 
assay solution was supplemented with 50 U/ml GDH and 1 mM NAD+ for glutamate 
detection. 
All experiments were performed on the stage of an epifluorescence (Nikon) 
microscope equipped with fluorescence microscopy. NADH fluorescence measurement and 
the fluorescence changes were expressed as dFZF0 (%) (F0 = fluorescence level before cells 
are stimulated, dF = Change in fluorescence). The light from a xenon arc lamp was delivered 
to the enzymatic assay solution in which the cells were bathed at 360 nm wavelength through 
60X oil immersion objective and the fluorescent emission collected through a dichroic mirror 
(Chroma) was detected using a quantex CCD camera. The changes in fluorescence were 
recorded for 300 seconds. 
Intracellular calcium imaging 
Krebs-Ringer bicarbonate buffer (KRB) containing 136 mM NaCl, 5 mM KC1, 1.2 
mM CaCh, 1.2 mM MgSC>4, 10 mM HEPES, 10 mM glucose, 0.1% BSA, pH 7.35 was used 
for all the [Ca2+]i measurements. [Ca2+]i measurements were performed using fura-2 dye. 
Briefly, cells were loaded with 2 [xM fura-2 AM for 30 min at room temperature after which 
the cells were washed with KRB. The fura-2 dye loaded cells were monitored for [Ca2+]i by 
using Nikon microscope connected to Quantex CCD camera and Metafluor software. 
Immunocytochemistry 
The astrocytes were identified and confirmed by their morphology and 
immunoreactivity to specific astrocytic marker glial fibrillary acidic protein (GFAP). 
Western blot analysis 
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The presence of specific A VP receptor subtypes was confirmed by their 
immunoreactivity to A VP receptor subtype specific antibodies after electrophoreisis and 
subsequent western blot. Briefly, 2 million astrocytes each from hippocampus and cerebral 
cortex cultures were lysed in a lysis buffer (Sigma CelLytic M) having protease inhibitors 
(Sigma protease inhibitor cocktail). 15 jug of protein from each lysate sample was separated 
by 10% SDS-PAGE. Subsequently, western blot analysis was performed by transferring the 
proteins to a nitrocellulose membrane and the membranes were probed with specific 
antibodies (1:700) for the presence of the receptor proteins. For the negative control only 
secondary antibodies were used to probe the nitrocellulose membrane. 
Data Analysis 
Unless mentioned all data are expressed as mean + S.E.M. with n = 3. EC50 and IC50 
values were calculated using graphpad prism software. One way ANOVA analysis was used 
to compare individual means using jmp(SAS) with the significance level set at p < 0.05. 
Results 
A VP (0.1 nM - 1000 nM) induced a concentration-dependent increase in glutamate 
release (Fig. 1) in the astrocytes from both the hippocampus and cerebral cortex with EC50 of 
0.76 + 0.08 nM and 0.86 + 0.16 nM respectively. A similar A VP (0.1 nM - 1000 nM)-
induced increase in [Ca2+]i was observed in astrocytes from the hippocampus and cortex 
(Fig.2) with the maximal increase at l|iM. The EC50 for A VP-induced increase in [Ca2+]; in 
astrocytes from hippocampus was 1.46 + 0.28 nM and in astrocytes from cortex was 1.31+ 
0.22 nM. For further investigations 1 nM A VP was used based on the EC50 values of A VP 
in its increase in [Ca2+]i and glutamate release. 
44 
To characterize the A VP receptor subtypes, specific antagonists were used to 
determine the inhibition of 1 nM A VP-induced increase in glutamate release and [Ca2],. 
Figs. 3 and 4 show the effects of 1 nM dP[Tyr(Me2)]AVP, a Vib receptor antagonist (Lee et 
al, 1995), and 1 nM WK-3-6, a Via receptor antagonist (Lee et al, 1995), on 1 nM AVP-
induced glutamate release from the hippocampal and cortical astrocytes. The Vib antagonist 
blocked the A VP-induced glutamate release from hippocampal astrocytes (Fig. 3) but had no 
effect in cortical astrocytes. In contrast, the Via antagonist blocked the A VP-induced 
glutamate release from the cortical astrocytes (Fig. 4) and had no effect on glutamate release 
from the hippocampal astrocytes. Fig.5 and Fig.6 show the effects of Vib and Via antagonists 
on 1 nM A VP-induced increase in [Ca2],. The Vib receptor antagonist abolished the effects 
of 1 nM A VP in a concentration-dependent manner in the hippocampal astrocytes with IC50 
of 0.88 + 0.15 nM, whereas 1 nM Via receptor antagonist had no effect (Fig.5). The Via 
receptor antagonist abolished the effects of 1 nM A VP in a concentration-dependent manner 
in the cortical astrocytes with IC50 of 0.98 + 0.13 nM, whereas 1 nM of the Vib receptor 
antagonist had no effect (Fig.6). SR-121463B, a non peptide V? receptor antagonist did not 
alter the 1 nM A VP-induced increase in [Ca2+]i in both hippocampal and cortical astrocytes 
(data not shown). 
Western blot data showed a strong presence of the Vib (Fig. 7a) receptor protein and a 
weak presence of Via (Fig. 7b) receptor protein in hippocampal astrocytes, whereas in 
cortical astrocytes only Via receptor protein was detected (Fig. 8a) and there was no detection 
of the Vib receptor protein (Fig. 8b). 
A VP has been reported to stimulate phospholipase A2 in several cell types and cell 
lines (Chen et al., 1999) and PLA2 enzymes have been shown to be involved in A VP-induced 
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signal transduction (Spatz et al., 1994). It has been postulated that accumulation of 
arachidonic acid (AA) in the astrocytes can inhibit glutamate reuptake (Marin et al., 1991), 
thus leading to accumulation of glutamate outside the cell, which in turn can activate 
metabotropic glutamate receptors on the membrane causing an increase in [Ca2+]i (Marin et 
al., 1993). In addition, glutamate increases [Ca2+]i in cultured astrocytes through 
metabotropic glutamate receptor mGluRS (Nakahara et al., 1997). Since A VP increased 
glutamate release and [Ca2+]i in the astrocytes, we investigated whether the increase in [Ca2+]i 
was at least partially due to the accumulation of glutamate in the media brought about by 
PLA2 activation and accumulation of AA. The metabotropic glutamate receptor antagonist 
CPCCOEt (Annoura et al., 1996; Hermans et al., 1998), at 100 |iM abolished the 1 |iM L-
glutamate-induced increase in [Ca2+]i, but had no effect on 1 nM A VP-induced increase in 
[Ca2+]i in astrocytes from both the hippocampus and the cerebral cortex (Fig. 9). 
Pretreatment of the astrocytes with 1 |iM ACA, a PLA2 inhibitor, failed to inhibit the 1 nM 
A VP-induced increase in [Ca2+]; (Fig. 10). 
Discussion 
Since the increase in [Ca2+]i can trigger glutamate release from astrocytes (Jeremic et 
al., 2001; Parpura et al.; 2004, Hua et al., 2004), we determined whether A VP, which elicits 
[Ca2+]i elevations in these cells, would evoke glutamate release. Indeed, A VP (0.1 - 1000 
nM) increased the glutamate release in a concentration-dependent manner. The 1 nM AVP-
induced increase in glutamate release and [Ca2+]i was blocked by dP[Tyr(Me2)]AVP, a Vib 
receptor antagonist (Lee et al., 1995), in the hippocampal astrocytes and by WK-3-6, a Via 
receptor antagonist (Lee et al., 1995), in the cortical astrocytes. The latter finding is in 
agreement with several studies on cortical astrocytes (Hatton et al., 1992) and in 
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disagreement with the report of Chen et al. (2000) who claimed Vib receptors mediate A VP-
induced increase in [Ca2+]i in cortical astrocytes. One explanation for this difference is the 
concentrations of the agonist A VP and the antagonists dP[Tyr(Me2)]AVP used in these 
studies. In the work by Chen et al. 1 |iM A VP was used along with 2.5 |iM Vib antagonist, 
which are rather high concentrations as opposed to 1 nM A VP and 1 nM Vib antagonist used 
in the present study. Since the Vib antagonist dP[Tyr(Me2)]AVP also has low affinity for Via 
receptors in rat liver (pK; of 8.36) (Arsenijevic et al., 1994), the concentration used by Chen 
et al. may have antagonized Via receptors as well. Nevertheless, our Western blot findings 
indicate that only Via receptors are expressed in the astrocytes isolated from cerebral cortex, 
whereas Vib receptors are expressed predominantly in the astrocytes isolated from 
hippocampus. Although others show the presence of Via (Ostrowski et al., 1992) and Vib 
mRNA transcripts in different regions of the brain (Christopher et al., 1998; Hurbin et al., 
1998), sufficient data in terms of actual receptor protein expression is lacking. To the best of 
our knowledge, the Western blot data from the present study are the first ones to demonstrate 
the A VP receptor protein expression in astrocytes. 
Since glutamate has been reported to increase [Ca2+]i in astrocytes through 
metabotropic glutamate receptors (Nakahara et al., 1997), we investigated whether the AVP-
induced increase in [Ca2+]i is due to the glutamate released by the astrocytes. The 
metabotropic glutamate receptor antagonist CPCCOEt failed to inhibit the A VP-induced 
increase in [Ca2+]i pointing in the direction that the glutamate release is secondary to the 
increase in [Ca2+];. Since PLA2 activation has been implicated in glutamate release (Marin et 
al., 1993), we also investigated the role of PLA2 in A VP-induced increase in [Ca2+];. The 
PLA2 inhibitor, ACA did not alter the A VP-induced increase in [Ca2],. Therefore, it is 
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unlikely that PLA2 or glutamate release plays a noticeable role in A VP-induced increase in 
[Ca2+]i in astrocytes. 
A VP has been functionally characterized as a regulator of cell volume and has been 
implicated in trauma-induced brain edema (O'Donnell et al., 2005). It has been shown to 
modulate regulated cell volume changes (Latzkovits et al., 1993; Sarfaraz et al., 1999; Hertz 
et al., 2000) in astrocytes and affect activation and translocation of aquaporins (Niermann et 
al., 2001). Inhibition of Ca2+/calmodulin-dependent protein kinase II can attenuate water 
permeability in astrocytes (Gunnarson et al., 2005) and glutamate can induce astrocytic 
swelling (Han et al., 2004; Hansson et al., 1994). Therefore, the resulting changes in 
astrocyte cell volume may be due to the combined effects of increased [Ca2+]i and glutamate 
release. Excess glutamate can lead to neuronal cell hyperexcitability and cell death, therefore 
astrocytes must have elaborate mechanisms working simultaneously to control the levels of 
extracellular glutamate as indicated by a report that astrocytes express the highest density of 
glutamate transporters (Huang et al., 2004). However, what physiological relevance does 
such A VP-induced release of glutamate through Ca2+-dependent mechanism has apart from 
neuronal excitation and synaptic plasticity within the nervous system warrants further 
investigation. Nevertheless, some of the toxic effects of A VP during brain trauma may be 
due to increased glutamate release. 
Our study demonstrated that A VP-induced increase in glutamate release and [Ca2+]i 
from astrocytes through Vib receptors in the hippocampal astrocytes and Via receptors in the 
cortical astrocytes. To the best of our knowledge this is the first report showing A VP-induced 
glutamate release and the presence of different receptor subtypes for A VP in astrocytes from 
different regions of brain. Neither the metabotropic glutamate receptor antagonist nor the 
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PLA2 inhibitor blocked the A VP-induced increase in [Ca2], suggesting that the glutamate 
release is secondary to the increase in [Ca2+];. However, it is not yet clear as to what 
differences may exist in Via- and Vib-based signaling mechanisms beyond the accompanying 
Ca2+ changes and glutamate release, since both receptors are mediated through Gq/n and 
PLC-p. The presence of different receptor subtypes for A VP in astrocytes from different 
regions of the brain suggests functional specializations of astrocytes from various regions of 
the brain and goes beyond the commonly accepted role of A VP as just a regulator of osmotic 
balance. Use of A VP receptor antagonists for treating brain edema and several cognitive and 
memory disorders have been proposed and Vi receptor antagonists have been shown to 
significantly decrease brain edema and play a neuroprotective role in brain trauma-induced 
edema (Kagawa et al., 1996). Since conditions like cerebral ischemia can increase water and 
A VP content even in the hippocampus (Liu et al., 1996), the use of more specific receptor 
antagonists aimed at both Via and Vib may show different, if not better, results. The 
understanding of the differential expression of the A VP receptor subtypes in different regions 
of the rat brain can be a novel approach to the use and therapeutic values of the A VP receptor 
specific agonists and antagonists. Treatments targeted at the A VP receptors needs to take into 
consideration this differential expression pattern, the effect of A VP on glutamate release and 
design methods of delivering the receptor specific treatments targeted to specific areas of 
brain. With the availability of nonpeptide antagonists for A VP receptors this approach might 
become possible. 
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Fig. 1. Effect of A VP on glutamate release from astrocytes. Glutamate release was measured 
indirectly as fluorescence of NADH in hippocampal (•) and cortical (A) astrocytes. Values 
are the mean + S.E. (n = cell preparations from 3 different rats). 
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Fig. 2. A VP-induced increase in [Ca2+]; in hippocampal (•) and cortical ( A )  astrocytes. 
Values are the mean + S.E. (n = cell preparations from 3 different rats). 
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Fig. 3. Effect of 1 nM dP[Tyr(Me2)]AVP (•), a Vib receptor antagonist, and 1 nM WK-3-6 
( ), a Via receptor antagonist, on A VP-induced increase in glutamate release from 
hippocampal astrocytes. *, p < 0.05 compared with the basal group. Values are the mean + 
S.E. (n = 3 n = cell preparations from 3 different rats). 
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Fig. 4. Effect of 1 nM WK-3-6 ( ), a Via receptor antagonist, and 1 nM dP[Tyr(Me2)]AVP 
(•), a Vib receptor antagonist, on A VP-induced increase in glutamate release from cortical 
astrocytes. *, p < 0.05 compared with the basal group. Values are the mean + S.E. (n = cell 
preparations from 3 different rats). 
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Fig. 5. Effect of dP[Tyr(Me )]AVP (•), a VIB receptor antagonist, and WK-3-6 ( ), a VIA 
receptor antagonist, on A VP-induced increase in [Ca2], in hippocampal astrocytes. *, p < 
0.05 compared with the basal group. Values are the mean + S.E. (n = cell preparations from 3 
different rats). 
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Fig. 6. Effect of WK-3-6 ( ), a Via receptor antagonist abolished and dP[Tyr(Me )]AVP 
(•), a Vib receptor antagonist on A VP- induced increase in [Ca2+]i in cortical astrocytes. *, p 
< 0.05 compared with basal. Values are the mean + S.E. (n = 3 independent cell 
preparations). 
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(a) (b) 
Fig. 7. Western blots of hippocampal astrocytes showed strong staining for anti-Vib (a) and a 
weak staining for anti-Via (b). Atleast 3 independent cell preparations were used. 
(a) (b) 
Fig. 8. Western blots of cortical astrocytes showed strong staining for anti-Via (a) and a weak 
staining for anti-Vib (b). 3 independent cell preparations were used. 
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Basal CPCCOEt + A VP CPCCOEt + Glut 
Fig. 9. Effect of CPCCOEt (•) a metabotropic glutamate receptor antagonist on AVP-
induced increase in [Ca2+]i and L-Glutamate-induced increase in [Ca2+]i in both hippocampal 
and cortical astrocytes. *, p < 0.05 compared with basal. Values are the mean + S.E. (n = 6 
independent cell preparations). Astrocytes from cerebral cortex and hippocampus were used. 
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Fig. 10. Effect of 100 |iM ACA (•) a PLA2 inhibitor on A VP-induced increase in [Ca2+]; in 
both hippocampal and cortical astrocytes. *, p < 0.05 compared with basal. Values are the 
mean + S.E. (n = 6 independent cell preparations). Astrocytes from cerebral cortex and 
hippocampus were used. 
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Chapter 3. Somatostatin inhibits forskolin-induced increase in cyclic AMP levels, 
intracellular Ca2+ concentrations and glutamate release via SSTR4 in rat astrocytes 
Nasser Syed, Catherine Martens, Walter H. Hsu. 
(To be submitted to the Journal of Neurochemistry) 
Abstract 
Increase in cAMP levels has been shown to facilitate glutamate release from nerve 
endings. Here we investigated the effects of somatostatin (SS), a Gi/0-coupled receptor 
activating hormone on lowering of cAMP level, [Ca2+]i, and glutamate release from neonatal 
rat astrocyte cultures. Forskolin (0.1 to 10 pM) increased glutamate release, cAMP levels and 
[Ca2+]i. in a concentration-dependent manner; forskolin-induced increase in [Ca2+]i paralleled 
the increase in glutamate release, but the increase in cAMP levels did not. S S alone did not 
have any effect on basal glutamate release, cAMP levels or [Ca2+]i, but inhibited the 
forskolin-induced glutamate release and increase in cAMP level in a concentration-dependent 
manner. SS also inhibited forskolin induced increase in [Ca2+]i. These effects were mimicked 
by the selective SSTR4 agonist L-803,087, but not by the selective agonists for SSTR1, 
SSTR2, SSTR3 or SSTR5. Although the inhibitory effect of SS and L-803,087 (1 nM to 1 
|iM) on forskolin-induced increase in cAMP levels and glutamate release was concentration-
dependent, the inhibition of glutamate release, however, was not apparent at >1 |iM of the 
agonists SS and L-803,087. This was probably due to the ability of SS and L-803,087 to 
increase [Ca2+]i at >1 pM. Pretreatment with U-73122, a phospholipase C inhibitor, blocked 
1 |xM SS-induced increase in [Ca2+]i. Our findings suggest: in astrocytes, 1) SS inhibits 
forskolin-induced glutamate release by decreasing cAMP levels and at least partly by 
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reducing [Ca2+];. 2) SSTR4 mediates SS-induced decrease in cAMP levels, [Ca2+]i and 
glutamate release. 3) SS at >1 |iM may increase glutamate release by activating 
phospholipase C pathway. SS and SSTR4 agonists could be used to reduce glutamate release 
from astrocytes. 
Key words: Somatostatin, Astrocytes, cAMP, Glutamate release, (3NAD. 
Somatostatin (SS), a peptide hormone synthesized in neurons, 5 cells of the pancreatic 
islets and other cells (Patel et al., 1999). It is present as a 14 amino-acid and a 28 amino-acid 
active forms (Ganong, 2001). The 14 amino-acid form is exclusive in enteric neurons, the 
retina and the 28 amino-acid form is the dominant one in neural tissue, endocrine pancreas 
and the stomach (Patel et al., 1999). Since its discovery as an inhibitor of growth hormone 
release, SS has been shown to be important for many functions in the brain, pituitary, 
pancreas, gastrointestinal tract, adrenals, thyroid, kidney and immune system (Ferone et al., 
2004). The actions of SS include inhibition of endocrine and exocrine secretions, modulation 
of neurotransmission, motor and cognitive functions, inhibition of intestinal motility, 
absorption of nutrients and ions, vascular contractility, and proliferation of cells (Guillermet-
Guibert et al., 2005). 
Somatostatin (SS) acts through specific G-protein coupled receptors (GPCRs) and to 
date, there are 5 subtypes of SS receptors whose distribution vary in different tissues (Reisine 
et al., 1993). Presence of genes for SSTR1, SSTR2 and SSTR4 have been reported in 
cultured rat astrocytes (Feindt et al., 1995) and genes for all 5 subtypes of SSTRs with low 
levels of SSTRS has also been reported in the various parts of rat brain (Feindt et al., 1995). 
SSTR2 and SSTR4 are expressed predominantly in cortical neurons along with low level 
expression of SSTR1, SSTR3 and SSTRS (Kumar, 2005). A recent report on endozepine 
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synthesis and release has also demonstrated the presence of SSTR1, SSTR2 and SSTR4 in 
astrocytes (Masmoudi et al., 2005). All the SSTRs are coupled to G, „ class of GPCRs, which 
upon activation, inhibit adenylyl cyclase activity, thus lowering cAMP levels. Upon binding 
of the agonist SS, the activated receptors exert mainly inhibitory and antiproliferative effects 
(Patel et al., 1999). SS is a known neurotransmitter/neuromodulator (Grouselle et al., 1998) 
and acts on both neurons and astrocytes (Krisch et al., 1994). SS inhibits glutamate release 
from neurons by activating SSTR2 (Grilli et al., 2004). In addition, SS has been shown to be 
important for cognitive functions (Dournaud et al., 1996). 
cAMP is a major intracellular signaling molecule that has been shown to increase 
glutamate release from astrocytes (Shiga et al., 2006) and neurons (Herrero et al., 1996; 
Dohovics et al., 2003). Adenylyl cyclase activation through Gs-coupled receptors; subsequent 
increase in cAMP levels and activation of cAMP-dependent protein kinase (PKA) is an 
important regulator for the glutamate release in neurons (Dohovics et al., 2003; Wang et al., 
2003, Grilli et al., 2004). Since SS inhibits adenylyl cyclase activity and has been shown to 
inhibit glutamate release from neurons (Dal Monte et al., 2003; Grilli et al., 2004), we 
investigated whether SS would inhibit glutamate release from astrocytes. If so, what would 
be the underlying mechanism of action? In addition, we characterized the subtype of SS 
receptors involved in SS-induced reduction of glutamate release and cAMP levels in cultured 
rat astrocytes. Our results suggest that SS decreases the forskolin-induced glutamate release, 
cAMP levels and [Ca2+]i in astrocytes and this effect is mediated by SSTR4. 
Materials and Methods 
Chemicals: Somatostatin, L-glutamic dehydrogenase (GDH), ^-nicotinamide adenine 
dinucleotide (PNAD), cAMP (Sigma chemical), fura-2 acetoxymethyl ester (fura-2AM) 
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(TEF Labs, Austin, TX), U-73122, U-73343 (Biomol), L-797,591, L-779,976, L-796,778, L-
803,087, L-817,818 (donated by Merck), TT-232 (donated by Dr. Keri Gyorgi, Hungary). 
Cell culture 
Cell cultures were established according to a previously described procedure (Jeftinija 
et al., 1996). Briefly primary culture of astrocytes was established from cells isolated from 
the cerebral cortex of 1 - 4 day old Sprague-Dewley rats. Following trypsinization, the cells 
were plated in culture flasks containing a-MEM supplemented with 10% FBS and 
maintained at 37°C until they reached 90% confluency. The confluent cultures were further 
processed to obtain enriched astrocyte type I cultures by preshaking at 260 RPM in an orbital 
shaker for 2 h to remove microglia and dividing astrocytes. After the preshaking, the media 
was changed and the cultures were shaken overnight at 260 RPM. Following the shaking the 
supernatant was discarded and the adhering astrocytes were trypsinized and resuspended in 
new flasks with FBS supplemented a-MEM. The cells were confirmed as astrocytes by their 
morphology and positive staining for glial fibrilary acidic protein (GFAP) marker using 
immunocytochemistry (Hsu et al., 1981). Cells from passage 2 to 6 were used for all the 
experiments. For glutamate measurement, cells were plated on 2-mm coverslips and used 
after they reached confluency by placing the cover slip in an open peri fusion chamber. For 
cAMP measurements, the astrocytes were plated in 12 well plates and were used when the 
cells reached 90% confluency. 
cAMP assay 
Krebs-Ringer bicarbonate buffer (KRB) containing 136 mM NaCl, 5 mM KC1, 1.2 
mM CaCh, 1.2 mM MgSC>4, 10 mM HEPES, 10 mM glucose, 0.1% BSA, pH 7.35 was used 
for all the cAMP measurements. After the astrocytes reached 90%, confluency media was 
70 
removed and cells were washed twice with KRB and were incubated with various treatments 
(forskolin, somatostatin, somatostatin receptor specific agonists and antagonists) for 15 min 
after which the cells were washed twice with KRB. The cells were detached from the wells 
using 0.01 N HC1 and transferred to glass tubes. This was followed by heat inactivation of 
the phosphodiesterases by immersing the tubes in 70° C water bath for 10 min. Subsequently, 
the extracts were centrifuged at 2000 x g for 5 minutes at 4° C, the supernatants were 
transferred to fresh tubes and neutralized with equal amounts of 0.01 N NaOH. cAMP 
concentrations were determined using radioimmunoassay as described previously (Richards 
et al., 1979). 
Glutamate measurement 
Glutamate levels were detected using an enzymatic assay as previously described 
(Nicholls et al., 1986; Nicholls et al., 1987; Ayoub et al., 1998; Innocent! et al., 2000). L-
glutamic dehydrogenase (GDH) ^-nicotinamide adenine dinucleotide (PNAD) to NADH in 
the presence of glutamate and NADH fluoresces when excited with UV light. By providing 
GDH and PNAD in the medium in which astrocytes are bathed, the glutamate released into 
the medium can be detected as an increase in NADH fluorescence signal. 
The enzymatic assay solution in which the cells were bathed was composed of NaCl, 
137 mM; KC1, 5 mM; MgCh, 2 mM; CaCh, 2 mM; HEPES, 10 mM; glucose, 10 mM. The 
assay solution was supplemented with 50 U/ml GDH and 1 mM NAD+ for glutamate 
detection. 
All experiments were performed on the stage of an epifluorescence (Nikon) 
microscope. NADH fluorescence measurement and the fluorescence changes were expressed 
as dFZFo (%) (F0 = fluorescence level before cells are stimulated, dF = Change in 
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fluorescence). The light from a xenon arc lamp was delivered to the enzymatic assay 
solution in which the cells were bathed at 360 nm wavelength through 60X oil immersion 
objective and the fluorescent emission collected through a dichroic mirror (Chroma) was 
detected using a quantex CCD camera. The changes in the fluorescence were recorded for 
300 seconds. 
Intracellular Ca2+ imaging 
KRB was used for all the [Ca2+]i measurements. [Ca2+]i measurements were performed 
using fura-2 dye. Briefly cells were loaded with 2 |iM fura-2 acetoxymethyl ester (fura-2AM) 
for 30 min at room temperature; subsequently the cells were washed with KRB and left for 
15 to 20 min for de-esteriflcation. The fura-2 dye loaded cells were monitored for [Ca2+]i by 
using Nikon diaphot microscope connected to Quantex CCD camera and Metafluor software. 
Immunocytochemistry 
The astrocytes were identified and confirmed by their morphology and 
immunoreactivity to specific astrocytic marker glial fibrillary acidic protein (GFAP) (Hsu et 
al., 1981). 
Data Analysis 
Unless mentioned, all data are expressed as mean + S.E. with n = 3. EC50 and IC50 
values were calculated using graphpad prism software. One way ANOVA was used to 
compare individual means using jmp(SAS) with the significance level set at p < 0.05. Basal 
group represents the basal level when no agonists or antagonists are used. 
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Results 
Forskolin-induced increase in glutamate release, cAMP levels and [Ca2+]i in astrocytes 
Forskolin (0.1 |iM - 10 pM) induced a concentration-dependent increase in glutamate 
release from astrocytes (Fig. 1) with maximal increase at 1 pM. The EC50 for forskolin-
induced increase in glutamate release was 95 + 18 nM. A similar forskolin (0.1 pM - 10 
pM)-induced increase in cAMP levels (Fig. 2) was observed with maximal increase at 10 
pM. The EC50 for forskolin-induced increase in cAMP levels was 135 + 13 nM. On an 
average, the 1 |iM forskolin induced a 4 fold increase in cAMP, whereas 10 |iM forskolin 
induced a 10 - 12 fold increase in cAMP over the basal. For all further experiments we used 
1 |iM forskolin to study the inhibitory effect of SS and SSTR agonists. Forskolin (1 nM - 10 
pM) also caused a concentration-dependent increase in [Ca2+]i with maximal increase at 1 
pM (Fig. 3). The EC50 for forskolin-induced increase in [Ca2+]i was 168 + 11 nM. The 
forskolin-induced [Ca2+]i increase paralleled that of glutamate release. 
Effect of SS on forskolin-induced glutamate release 
S S (100 nM) alone did not have any effect on glutamate release from the astrocytes, 
but SS (10 nM & 100 nM) decreased the forskolin (1 pM)-induced glutamate release in a 
concentration-dependent manner with maximal decrease at 100 nM (Fig. 4). However, at 1 
pM, SS did not inhibit the glutamate release. The IC50 for SS-induced decrease in glutamate 
release was 6 + 3 nM. 
Effect of SS on forskolin-induced increase in cAMP levels 
SS alone even at 1 |iM did not have any effect on basal cAMP levels in astrocytes 
(data not shown), but SS (0.1 pM & 1 pM) inhibited the forskolin (1 pM)-induced increase 
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in intracellular cAMP levels in a concentration-dependent manner with maximal inhibition at 
1 |iM (Fig. 5). The IC50 for SS-induced inhibition of cAMP levels was 112 + 7 nM. 
Effect of SS on forskolin-induced increase in [Ca2+]i. 
Since forskolin increased [Ca2+]; in astrocytes, we determined if SS would inhibit the 
forskolin-induced increase in [Ca2+];. SS (0.1 |iM) alone did not have any effect on [Ca2+]i, 
but reduced the forskolin (1 |iM)-induced increase in [Ca2+];(Fig. 6). 
Effect of SSTR agonists on forskolin-induced increase in cAMP levels 
Initially, all 5 SSTR agonists were tested at 0.1 |iM to determine which of them would 
inhibit the forskolin (1 |iM)-induced increase in cAMP levels. SSTR1 agonist L-797,591, 
SSTR2 agonist L-779,976, SSTR3 agonist L-796,778, and SSTR5 agonist L-817,818 failed 
to inhibit the forskolin-induced increase in cAMP levels (Fig. 7). In contrast, SSTR4 agonist 
L-803,087 (0.1 |iM) inhibited the forskolin-induced increase in cAMP levels. 
Concentration-dependency of L-803,087 in inhibiting forskolin-induced increase in 
cAMP levels 
L-803,087 (1 nM - 1 |iM) inhibited the forskolin-induced increase in cAMP levels in a 
concentration-dependent manner with 1 |iM causing the maximal inhibition (Fig. 8). The 
IC50 for L-803,087-induced inhibition of cAMP levels was 5 + 3 nM. 
Effect of L-803,087 on forskolin-induced glutamate release 
L-803,087 (10 nM & 100 nM) decreased the forskolin-induced glutamate release with 
maximal decrease at 100 nM; but at >1 |iM L-803,087 failed to inhibit the forskolin-induced 
glutamate release (Fig. 9). The IC50 for L-803,087-induced inhibition of glutamate release 
was 7 + 2 nM. 
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Effect of SSTR4 antagonist TT-232 on SS- and L-803,087-induced decrease in cAMP 
levels 
Pretreatment with TT-232 (10 |iM) blocked the SS- and L-803,087-induced inhibition 
of cAMP levels (Fig. 10). TT-232 (10 |iM), a specific SSTR4 antagonist (Weckbecker et al., 
2003), alone at 10 |iM did not have any effect on cAMP levels. 
Effect of SS and L-803,087 on [Ca2+]i in astrocytes 
Since SS and L-803,087 at > 1 |iM failed to inhibit the forskolin-induced glutamate 
release, this suggested these agonists may exert a stimulatory effect in addition to the 
inhibitory effect. Thus, we investigated if S S and L-803,087 would elicit an increase in 
[Ca2+]i. SS and L-803,087 (1 nM - 100 nM) had no effect on [Ca2+]; in astrocytes; however, 
at >1 |iM, both SS and L-803,087 increased the [Ca2+]i (Figs. 11a & lib). The SS-induced 
increase in [Ca2+]; was blocked by 1 |iM U-73122, a phospholipase C (PLC) inhibitor, while 
its structural analog U-73343, which does not inhibit PLC, had no effect on SS-induced 
increase in [Ca2+]i (Fig. 12). These results suggest that SS-induced increase in [Ca2+]i is 
through activation of PLC. Neither U-73122 alone nor U-73343 alone caused any significant 
changes in [Ca2+]i (data not shown). 
Discussion 
The results in the present study provide for the first time evidence that SS inhibits 
forskolin-induced glutamate release from astrocytes. SS has been traditionally shown to be 
inhibitory in function; in the CNS it has been shown to inhibit glutamate release from the 
neurons of the cerebral cortex (Grilli et al., 2004) and retina (Dal Monte et al., 2003). The 
effects of SS on astrocytes beyond lowering of cAMP levels are still not well-understood, but 
it has been shown to inhibit endozepine release from astrocytes (Masmoudi et al., 2005). 
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Here we showed that SS not only reduced the forskolin-induced increase in cAMP levels and 
[Ca2+]i, but it also reduced the forskolin-induced glutamate release. 
Cyclic AMP, a major signaling molecule that has been shown to induce glutamate 
release from astrocytes (Shiga et al., 2006), activates L-type voltage-dependent Ca2+ channels 
in astrocytes (Barres et al., 1989) and enhances capacitative Ca2+ entry (Wu et al., 1999; 
Grimaldi et al., 1999). SS has been shown to inhibit Ca2+ influx though L-type channels in rat 
neurons (Johnson et al., 2001) and human neuroendocrine tumor cells of the gut (Glassmeier 
et al., 1998). Since SS is a known inhibitor of adenylyl cyclase, the reduction in glutamate 
release by SS and L-803,087, a SSTR4 agonist, in astrocytes may be through a similar 
adenylyl cyclase-PKA dependent pathway as in the SS-induced inhibition of glutamate 
release from cortical neurons (Grilli et al., 2003). Interestingly, the glutamate release was 
inhibited only at agonist concentrations of <100 nM; at >1 |iM, SS and L-803,087 did not 
inhibit the forskolin-induced glutamate release. Since the increase in [Ca2+]i can trigger 
glutamate release from astrocytes (Jeftinija et al., 2001; Parpura et al., 2004; Takano et al., 
2005; Montana et al., 2004), the failure to inhibit glutamate release by SS and L-803,087 
may be due to their ability to increase [Ca2+]i at >1 |iM. SS has been shown to activate PLC 
and increase [Ca2+]i in COS-7 cells (Akbar et al., 1994), smooth muscle cells (Murthy et al., 
1996) and NG108-15 cells (Rhie et al., 2003). We further showed that U-73122, a PLC 
inhibitor, blocked SS-induced increase in [Ca2+]i, suggesting this increase is mediated by 
IP3-mediated Ca2+ release from the endoplasmic reticulum. 
SSTR1, 2 and 4 have been found in cultured astrocytes (Feindt et al., 1995; Masmoudi 
et al., 2004). However, in the present study, SSTR4 seemed to be the only one that was 
consistently expressed, since SSTR4 agonist and antagonist were the only pharmacologic 
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agents that influenced cAMP levels and glutamate release in astrocytes. One reason for a 
strong expression of SSTR4 in our astrocytes cultures could be due to the difference in tissue 
collection and culture conditions. The cerebral cortex was collected in the present study, but 
cerebral hemispheres were collected by Masmoudi et al. (2005). We used a-MEM media as 
opposed to DMEM/Ham's F12 used by Masmoudi et al. The study by Feindt et al. (1995) 
used RT-PCR to probe only for the presence of gene transcripts for different SSTR subtypes, 
however no assays were done to look into actual receptor expression. In addition, SS has 
been shown to inhibit glutamate release from cerebrocortical neurons (Grilli et al., 2004) and 
mouse retinal cells (Dal Monte et al., 2003) through SSTR2. In the present study, we showed 
that SS decreased cAMP levels and glutamate release from cultured neonatal rat astrocytes 
through SSTR4. An important outcome of these studies is the potential targets for drugs to 
alleviate the effects of excessive glutamate transmission and glutamate induced neurotoxicity 
and more specific therapeutic interventions. 
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Basal 10000 
Forskolin, nM 
Fig. 1. Effect of forskolin on glutamate release from astrocytes. *, p < 0.05 compared with 
the basal group. Values are the mean + S.E. (n = 4 independent cell preparations). 
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* 
250 i 
Basal 1 10 100 1000 10000 
Forskolin, nM 
Fig. 2. Effect of forskolin on cAMP levels in astrocytes. Each value is expressed as a 
percentage of control (1 |iM forskolin (•)). *, p < 0.05 compared with the basal group. 
Values are the mean + S.E. (n = 3 independent cell preparations). 
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Basal 10 100 
Forskolin, nM 
1000 10000 
Fig. 3. Effect of forskolin on [Ca2+];. Forskolin induced a concentration-dependent increase 
in [Ca2+]i with maximal increase at 1 |iM. Values are the mean + S.E. (n = 3 independent cell 
preparations with >15 cells per experiment). 
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Forskolin, 1 |JM 
Basal Control 10 100 1000 
SS, nM 
Fig. 4. Effect of SS on forskolin-induced increase in glutamate release. *, p < 0.05 compared 
with control (1 |iM Forskolin). Values are the mean + S.E. (n = 3 independent 
preparations). 
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Basal Control 10 
Forskolin, 1 |JM 
100 1000 
SS, nM 
10000 
Fig. 5. Effect of SS on forskolin-induced increase in cAMP levels, expressed as percentage 
of control (1 |iM forskolin). *, p < 0.05 compared with control. Values are the mean + S.E. (n 
= 3 independent cell preparations). 
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Forskolin 
SS + Forskolin 
Time (Sees) 
Fig. 6. Effect of SS on forskolin-induced increase in [Ca2+];. SS (100 nM) decreased but did 
not abolish the 1 |iM forskolin-induced increase in [Ca2+];. The graph shows a representative 
trace of [Ca2+]i from 3 experiments with >15 cells per experiment. 
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Basal Control SS 
Forskolin, 1 |JM 
L-797,591 L-779,976 L-796,778 L-803,087 L-817,818 
Fig. 7. Effect of SSTR agonists on forskolin-induced increase in cAMP levels expressed as 
percentage of control (1 |iM forskolin). All 5 SSTR agonists were tested at 100 nM 
concentration. *, p < 0.05 compared with control. Values are the mean + S.E. (n = 3 
independent cell preparations). 
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Forskolin, 1 |JM 
Basal Control <U 1 10 100 1000 10000 
L-803,087, nM 
Fig. 8. Effect of SSTR4 agonist, L-803,087 (100 pM - 10 |aM) on 1 forskolin-induced 
increase in cAMP levels expressed as percentage of control (1 pM forskolin). *, p < 0.05 
compared with control. Values are the mean + S.E. (n = 3 independent cell preparations). 
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Forskolin, 1 |JM 
Basal Control 10 100 1000 
L-803,087, nM 
Fig. 9. Effect of SSTR4 agonist, L-803,087 (10 nM - 1 |iM) on forskolin-induced increase in 
glutamate release. *, p < 0.05 compared with control (1 |iM Forskolin). Values are the mean 
+ S.E. (n = 3 independent cell preparations). 
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Basal 
Forskolin, 1 |JM 
SS, 100 nM 
Control 
L-803,087,100 nM 
TT-232 
Fig. 10. Pretreatment with TT-232 (10 |iM) antagonized the SS (100 nM)- and SSTR4 
agonist L-803,087 (100 nM)-induced decrease in cAMP levels. cAMP levels expressed as 
percentage of control (1 |iM forskolin). *, p < 0.05 compared with control. Values are the 
mean + S.E. (n = 3 independent cell preparations). 
92 
180 -, SS (1 nM) 
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1 100 -
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0 240 
Time (Sees) 
Fig. 11a. SS (1 |iM)-induced increase in [Ca2+];. The graphs are representative traces from 
four experiments with >15 cells per experiment 
180 -| L-803,087 (1 fiM) 
160 -
140 -
•3 120 -
1 100 -
60 -
40 
240 0 
Time (Sees) 
Fig. lib. L-803,087 (1 |iM)-induced increase in [Ca2+];. The graphs are representative traces 
from four experiments with >15 cells per experiment. 
Basal U-73122 + SS U-73343 + SS 
Fig. 12. Effect of U-73122 and U-73343 (1 |iM) on SS (1 |iM)-induced increase in [Ca2+];. *, 
p < 0.05 compared with SS. Values are the mean + S.E. (n = 3 independent cell preparations 
with >15 cells per experiment). 
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